| [1] Huang HC, Klein PS. Frizzled family: receptors for multiple signal transduction pathways. Genome Biol. 2004;5(7):234.[2] Cappuccio I, Calderone A, Buseeti CL, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J Neurosci. 2005;25(10):2647-2657.[3] Glinka A, Wu W, Delius H, et a1. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357-362.[4] Lee AY, He B, You L, et al. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun. 2004; 323(4): 1246-1250.[5] Endo Y, Beauchamp E, Woods D, et al. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3-and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol. 2008;28(7):2368-2379.[6] Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417(6889):664-667.[7] Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411(6835): 321-325.[8] Martin TJ, Sims NA, Ng KW. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int. 2008;19(8):1125-1138.[9] Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age (Dordr). 2008; 30(4): 273-282.[10] Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133(16): 3231-3244.[11] Rawadi G, Vayssiere B, Dunn F, et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 2003;18(10): 1842-1853.[12] Glass DA 2nd, Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol. 2006;73:43-84.[13] Qiang YW, Barlogie B, Rudikoff S, et al. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008;42(4):669-680.[14] Li J, Sarosi L, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006; 39(4):754-766.[15] Morvan F, Boulukos K, Clement-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6): 934-945.[16] MacDonald BT, Joiner DM, Oyserman SM, et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone. 2007; 41(3):331-339.[17] Glantschnig H, Hampton R, Wei N, et al. Fully human anti-DKK1 antibodies increase bone formation and resolve osteopenia in mouse models of estrogen deficiency induced bone loss. J Bone Miner Res. 2008;23(Suppl.S):S60-S61.[18] Butler JS, Queally JM, Devitt BM, et al. Silencing DKK1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation. BMC Musculoskelet Disord. 2010;11:210.[19] Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010; 69(12):2152-2159.[20] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.[21] Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24(3):425-436.[22] Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med. 2007;13(2):133-134.[23] Yaccoby S, Ling W, Zhan F, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106-2111.[24] Reppe S, Refvem H, Gautvik VT, et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. Bone. 2010;46(3):604-612.[25] Wang FS, Ko JY, Lin Cl, et al. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histormorphological study in ovaricetomized rats. Bone. 2007;40(2):485-492.[26] Wang FS, Ko JY, Yeh DW, et al. Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology. 2008;149(4):1793-1801.[27] Glantschnig H, Hampton RA, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010;285(51):40135-40147.[28] Glantschnig H, Scott K, Hampton R, et al. A rate-limiting role for dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther. 2011;338(2):568-578.[29] Voskaridou E, Christoulas D, Xirakia C, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 2009;94(5):725-728.[30] Zhang W, Drake MT. Potential Role for Therapies Targeting DKK1, LRP5, and Serotonin in the Treatment of Osteoporosis. Curr Osteoporos Rep. 2012;10(1):93-100.[31] Weng LH, Wang CJ, Ko JY, et al. Control of Dkk-1 ameliorates chondrocyte apoptosis, cartilage destruction, and subchondral bone deterioration in osteoarthritic knees. Arthritis Rheum. 2010;62(5):1393-1402.[32] Marshal MJ, Evans SF, Sharp CA, et al. Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin Biochem. 2009; 42(10-11):965-969.[33] Polzer K, Diarra D, Zwerina J, et al. Inflammation and destruction of the joints: the Wnt pathway. Joint Bone Spine. 2008;75(2):105-107.[34] Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol. 2008;140(1):25-35.[35] Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb(BHQ880) as a potential therapeutic for multiple myeloma. Blood. 2009;114(2):371-379.[36] Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24(3):425-436,9. |
